

03-27-00

Please type a plus (+) sign in this box → ☐

EXPRESS MAILING LABEL NO.
EL108178214US

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new non-provisional applications under 37 CFR 1.53(b))</i>		Attorney Docket No. DM6993
		First Named Inventor or Application Identifier LAZEWATSKY
		Express Mail Label No. EL108178214US
		Express Mailing Date March 24, 2000

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent applications contents.		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231	
<p>1. <input checked="" type="checkbox"/> Fee (Authority to charge deposit account below.) <i>(Submit an original, and duplicate for fee processing)</i></p> <p>2. <input checked="" type="checkbox"/> Specification [Total Pages 51] <i>(preferred arrangement set forth below)</i></p> <ul style="list-style-type: none">- Descriptive title of the invention- Cross Reference to Related Application (if needed)- Statement Regarding Fed sponsored R&D (if needed)- Reference to Microfiche Appendix (if needed)- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings (if filed)- Detailed Description- Claims [No. of Claims 19]- Abstract of the Disclosure <p>3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Pages 1]</p> <p>4. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages 1]</p> <ul style="list-style-type: none">a. <input checked="" type="checkbox"/> Unexecuted (original or copy)b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d) <i>(for continuation/divisional with Box 14 completed)</i>i. <input type="checkbox"/> DELETION OF INVENTORS Signed Statement below at 15 deleting inventor(s) named in the prior application see 37 CFR 1.63(d)(2) and 1.33(b). <p>5. <input type="checkbox"/> Incorporation by Reference (useable if Box 4b is The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p>		<p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. Nucleotide and/or Amino Acid Sequence Submissions <i>(if applicable, all necessary)</i></p> <ul style="list-style-type: none">a. <input type="checkbox"/> Computer Readable Copyb. <input type="checkbox"/> Paper Copy (identical to computer copy)c. <input type="checkbox"/> Statement verifying identity of above copies	
ACCOMPANYING APPLICATION PARTS			
<p>8. <input checked="" type="checkbox"/> Power of Attorney</p> <p>9. <input type="checkbox"/> Information Disclosure Statement (IDS) Cover Letter plus PTO-1449 Copies of IDS Citations</p> <p>10. <input checked="" type="checkbox"/> Preliminary Amendment</p> <p>11. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>12. <input type="checkbox"/> Certified Copy priority Document(s) <i>(if foreign priority is claimed)</i></p> <p>13. <input type="checkbox"/> Other</p>			
<p>- If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) f prior Application No.:</p>			
<p>15. <input type="checkbox"/> DELETION OF INVENTOR(S) STATEMENT: This application is being filed by less than all the inventors named in the prior application. In accordance with 37 CFR 1.63(d)(2) and 1.33(b), the Assistant Commissioner is requested to delete the number(s) of the following person or persons who are not inventors of the invention being claimed in this application:</p>			
<p>16. <input checked="" type="checkbox"/> Amend the specification by inserting before the first line the sentence: This application claims the benefit of U.S. Provisional Application No. 60/126,359 filed on March 26, 1999</p>			
<p>17. <input type="checkbox"/> Cancel in this application original claims of the prior application before calculating the filing. (At least one Original independent claim must be retained for filing purposes.)</p>			
<p>18. <input type="checkbox"/> Priority of foreign Application No. _____ filed on _____ in _____ (country) is claimed under 35 U.S.C. 119.</p>			

3577 U.S. PTO

03/24/00

35 U.S. PTO

03/24/00

03/24/00 03/24/00

CLAIMS	(1) FOR	(2) NUMBER FIELD	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c))	19- (20) =	0	x \$ (18) =	\$0
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	4 - (3) =	1	1x \$ (78)=	\$78
	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			= \$270 =	
				BASIC FEE (37 CFR 1.16(a))	\$690.00
				TOTAL =	\$768.00

19. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 04-1928:

a. ☒ Fees required under 37 CFR 1.16.

b. ☐ Fees required under 37 CFR 1.17

20. ☐ Other:

21. CORRESPONDENCE ADDRESS					
NAME	Maureen P. O'Brien				
ADDRESS	DuPont Pharmaceuticals Company c/o E. I. du Pont de Nemours and Company Legal - Patents 1007 Market Street				
CITY	Wilmington	STATE	Delaware	ZIP CODE	19898
COUNTRY	U.S.A.	TELEPHONE	302-992-4528	FAX	302-992-4878

22. SIGNATURE OF ATTORNEY OR AGENT REQUIRED	
NAME	Maureen P. O'Brien
SIGNATURE	Maureen P. O'Brien
DATE	March 24, 2000